(VIANEWS) – Shares of BIOSENIC (BEL 20: BIOS.BR) rose by a staggering 23.2% in 10 sessions from €0.1 to €0.12 at 20:09 EST on Thursday, following the last session’s downward trend. BEL 20 is rising 0.97% to €3,717.30, after two successive sessions in a row of losses.
About BIOSENIC
BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures. The company is based in Mont-Saint-Guibert, Belgium.
Earnings Per Share
As for profitability, BIOSENIC has a trailing twelve months EPS of €-0.02.
Volatility
BIOSENIC’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.42%, a negative 0.13%, and a positive 4.52%.
BIOSENIC’s highest amplitude of average volatility was 3.64% (last week), 5.04% (last month), and 4.52% (last quarter).
Volume
Today’s last reported volume for BIOSENIC is 10521 which is 98.88% below its average volume of 226170.
More news about BIOSENIC (BIOS.BR).
